RNAi Therapeutics
-
Vutrisiran Shows Long-Term Cardiovascular Benefit in ATTR-CM: New Data from Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025
Alnylam Pharmaceuticals’ AMVUTTRA (vutrisiran) showed sustained benefits in transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) patients in the HELIOS-B Phase 3 study. Data presented at ESC Congress 2025 revealed that vutrisiran reduced the risk of all-cause mortality or first cardiovascular event by 37% in the overall population and 42% in the monotherapy group over 48 months. The open-label extension maintained improvements in quality of life and cardiac biomarkers, supporting vutrisiran as a potential first-line ATTR-CM therapy.
